Search research articles
Contact Us
Filters
Showing results (11-20 of 47) with videos related to
Page
of 5
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease
|
June 29, 2018
Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD
Colin Reisner, James Pearle, Edward M Kerwin, et al.
Clinical Therapeutics
|
April 8, 2020
Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults
Paul Dorinsky, Paolo DePetrillo, Kiernan DeAngelis, et al.
Advances in Therapy
|
April 2, 2023
Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis"
Jonathan Marshall, Akanksha Sharma, Patrick Darken, et al.
Pulmonary Pharmacology & Therapeutics
|
December 17, 2019
Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD
Leonard J Dunn, Edward M Kerwin, Kiernan DeAngelis, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
May 19, 2018
Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD
Edward M Kerwin, Thomas M Siler, Samir Arora, et al.
Chest
|
September 13, 2003
The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD
Nicola A Hanania, Patrick Darken, Donald Horstman, et al.
Therapeutic Advances in Respiratory Disease
|
December 24, 2019
Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β<sub>2</sub>-agonist fixed-dose combinations in COPD
Mohd Kashif Siddiqui, Pragya Shukla, Martin Jenkins, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
February 5, 2021
Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS
Fernando J Martinez, Gary T Ferguson, Eric Bourne, et al.
Therapeutic Advances in Respiratory Disease
|
August 25, 2021
Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler <i>versus</i> dual therapies in patients with COPD: a sub-study of the ETHOS trial
Klaus F Rabe, Fernando J Martinez, Dave Singh, et al.
Chest
|
July 20, 2017
Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD
Fernando J Martinez, Leonardo M Fabbri, Gary T Ferguson, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 47) with videos related to
Sort By:
Page
of 5
International Journal of Chronic Obstructive Pulmonary Disease
|
June 29, 2018
Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD
Colin Reisner, James Pearle, Edward M Kerwin, et al.
Clinical Therapeutics
|
April 8, 2020
Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults
Paul Dorinsky, Paolo DePetrillo, Kiernan DeAngelis, et al.
Advances in Therapy
|
April 2, 2023
Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis"
Jonathan Marshall, Akanksha Sharma, Patrick Darken, et al.
Pulmonary Pharmacology & Therapeutics
|
December 17, 2019
Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD
Leonard J Dunn, Edward M Kerwin, Kiernan DeAngelis, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
May 19, 2018
Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD
Edward M Kerwin, Thomas M Siler, Samir Arora, et al.
Chest
|
September 13, 2003
The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD
Nicola A Hanania, Patrick Darken, Donald Horstman, et al.
Therapeutic Advances in Respiratory Disease
|
December 24, 2019
Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β<sub>2</sub>-agonist fixed-dose combinations in COPD
Mohd Kashif Siddiqui, Pragya Shukla, Martin Jenkins, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
February 5, 2021
Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS
Fernando J Martinez, Gary T Ferguson, Eric Bourne, et al.
Therapeutic Advances in Respiratory Disease
|
August 25, 2021
Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler <i>versus</i> dual therapies in patients with COPD: a sub-study of the ETHOS trial
Klaus F Rabe, Fernando J Martinez, Dave Singh, et al.
Chest
|
July 20, 2017
Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD
Fernando J Martinez, Leonardo M Fabbri, Gary T Ferguson, et al.
Page
of 5